Director/PDMR Shareholding

Haleon PLC

13 March 2026

 

​Haleon plc: Director/PDMR Shareholding 

13 March 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

This notification sets out the details of the grant of Haleon share awards over Ordinary Shares made to PDMRs under the Haleon Performance Share Plan and Deferred Annual Bonus Plan.

The Performance Share Plan main awards are subject to performance conditions over the performance period ending on 31 December 2028. Performance targets are disclosed in the 2025 Annual Report and 20-F.

All awards were made in line with the principles of Haleon's Directors' Remuneration Policy and are subject to malus and clawback provisions.

1	Details of the issuer or emission allowance market participant
a)	Name of the entity	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment to prior notifications	Initial Notification
3	Details of the person discharging managerial responsibilities / person closely associated ("PCA")
a)	PDMR/PCA	PDMR
b)	Name	Brian McNamara
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of Instrument	Share
	Identification code	GB00BMX86B70
b)	Nature of the transaction	(i)       Grant of a conditional award under the Haleon plc Performance Share Plan (ii)      Grant of a conditional award under the Haleon plc Deferred Annual Bonus Plan
c)	Currency, Price(s) and Volume(s)
				Price(s)	Volume(s)
			(i)	Nil	1,639,855
			(ii)	Nil	173,825
d)	Aggregated information
	- Aggregated volume	1,813,680
	- Price	Nil
e)	Date of the transaction	12 March 2026
f)	Place of the transaction	Outside a trading venue

1	Details of the issuer or emission allowance market participant
a)	Name of the entity	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment to prior notifications	Initial Notification
3	Details of the person discharging managerial responsibilities / person closely associated ("PCA")
a)	PDMR/PCA	PDMR
b)	Name	Dawn Allen
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of Instrument	Share
	Identification code	GB00BMX86B70
b)	Nature of the transaction	(i)       Grant of a conditional award under the Haleon plc Performance Share Plan (ii)      Grant of a conditional award under the Haleon plc Deferred Annual Bonus Plan
c)	Currency, Price(s) and Volume(s)
				Price(s)	Volume(s)
			(i)	Nil	712,784
			(ii)	Nil	95,513
d)	Aggregated information
	- Aggregated volume	808,297
	- Price	Nil
e)	Date of the transaction	12 March 2026
f)	Place of the transaction	Outside a trading venue

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

For more information, please visit www.haleon.com. 

 

END